20 results about "Ropivacaine" patented technology

The invention relates to the technical field of gel preparations, in particular to ropivacaine phospholipid gel as well as a preparation method and application thereof. The invention provides ropivacaine phospholipid gel. The ropivacaine phospholipid gel is prepared from ropivacaine, mixed lipid and a hydration solvent, wherein the mixed lipid comprises neutral phospholipid, negative phospholipid and cholesterol, the neutral phospholipid comprises at least one of phosphatidylcholine and phosphatidylcholine derivatives, and the negative phospholipid is phosphatidic acid or phosphatidylglycerol. According to the ropivacaine phospholipid gel, the encapsulation effect and the release characteristic of the ropivacaine phospholipid gel are improved by improving phospholipid raw materials and a preparation process.

The application relates to the field of medical devices, in particular to a tracheal cannula end balloon, a preparation method thereof and a tracheal cannula. The tracheal cannula end balloon comprises a balloon body and a double-layer structure arranged on the surface of the balloon body, and the double-layer structure comprises a first nanofiber membrane and a second nanofiber membrane; the first nanofiber membrane comprises a first matrix material and paclitaxel, and the first matrix material comprises polyethylene glycol and polycaprolactone; the second nanofiber membrane comprises a second matrix material and ropivacaine, and the second matrix material comprises polyethylene glycol and polyvinylpyrrolidone. In the application, the double-layer structure design realizes layered release of the drugs, the outer-layer drugs rapidly relieve pain and inflammation, and the inner-layer drugs continuously inhibit cell proliferation, so that the problems caused by the tracheal cannula end balloon are comprehensively solved.

The invention belongs to the technical field of biological medicine, and particularly discloses a sprayable double-network hydrogel microsphere adhesive and a preparation method and application thereof.The preparation method comprises the following steps that liquid paraffin, sorbitan monooleate and polyoxyethylene sorbitan monolaurate serve as oil phases, and an emulsion is formed; fully mixing the emulsion with petroleum ether, centrifugally separating gel microspheres, freeze-drying, and storing in a dark place; preparing a ropivacaine liposome; and adding ultrapure water into the lipid membrane to obtain a primary liposome suspension, adsorbing the liposome by using the hydrogel microspheres, and collecting the obtained dual-network hydrogel microspheres. According to the sprayable double-network hydrogel microsphere adhesive as well as the preparation method and the application thereof, prepared hydrogel microspheres can quickly and consistently cover irregular wounds, and liposome loaded with ropivacaine provides continuous analgesic release, so that the painful wound healing effect is improved. By simultaneously solving the problems of maintaining continuous adhesion and prolonging pain relief in blood-saturated wounds.

FIELD: plastic surgery.SUBSTANCE: under aseptic conditions and endotracheal anesthesia, hydropreparation of the subcutaneous fat tissue is performed with 0.04% ropivacaine solution 60.0 ml with adrenaline 1:100000, a skin incision in the area of the submammary groove of the mammary gland of 3.5–4.0 cm in length is made, the tissues are dissected layer by layer to the fascia of the pectoralis major muscle. A dissection is performed in the Chassignac space to the level of the lower pole of the areola or an incision is made in the skin in the area of the mammary gland along the lower semicircle of the areola, the tissues are perpendicularly dissected layer by layer to the fascia of the pectoralis major muscle. Next, dissection is performed in the Chassignac space to the level of the submammary groove, and the lateral edge of the right pectoralis major muscle is isolated. The retropectoral pocket for the implant is formed using blunt and sharp methods. The lower medial bundle of the pectoralis major muscle is mobilized to the level of 4 o'clock on a conventional clock dial for the right breast and to the level of 8 o'clock on a conventional clock dial for the left breast. Partial vertical myotomy of the free muscle flap is performed. The distal fragments of the pectoralis major muscle are fixed at three points to the posterior surface of the gland with an atraumatic Vikryl 2-0 thread at the level of the nipple-areolar complex. A silicone implant is placed into the formed pocket, and the implant is evenly distributed and centered within it.EFFECT: preventing uncontrolled cranialization of the pectoralis major muscle flaps during vertical myotomy in dual-plane augmentation mammoplasty.1 cl, 2 ex

The invention belongs to the field of medicine preparation and medicine preparations, and particularly relates to a preparation method and application of ropivacaine or pharmaceutically acceptable salt thereof, the ropivacaine or the pharmaceutically acceptable salt thereof exists in a particle form, such as a crystal form, preferably a regular crystal form, such as a rod-like crystal form or a bulk crystal form, and the ropivacaine or the pharmaceutically acceptable salt thereof exists in a crystal form. The median diameter D50 is 1 [mu] m to 40 [mu] m, preferably 3 [mu] m to 40 [mu] m, and more preferably 5 [mu] m to 40 [mu] m; the invention further relates to application of the ropivacaine or the pharmaceutically acceptable salt of the ropivacaine prepared by the method in preparing a suspension of the ropivacaine or the pharmaceutically acceptable salt of the ropivacaine or a sterile solid composition preparation of the ropivacaine or the pharmaceutically acceptable salt of the ropivacaine, wherein the sterile solid composition preparation can be redissolved to obtain the suspension of the ropivacaine or the pharmaceutically acceptable salt of the ropivacaine. The suspension prepared by the method is simple in method, free of shearing and homogenizing treatment, easy to administrate and small in irritation, and has good medication safety and tolerance.

This invention belongs to the field of nanomedicine technology, specifically relating to a pH / hypoxia dual-responsive polymer, nanomicelles, their preparation method, and applications. The pH / hypoxia dual-responsive polymer is a hydroxyethyl deacetylated chitosan modified with p-nitrobenzyl chloroformate and cinnamaldehyde. Ropivacaine is loaded onto it and prepared into nanomicelles for use as a drug delivery system after tumor surgery. Due to its acid sensitivity and hypoxia response, it can intelligently identify the tumor microenvironment, achieving precise drug delivery.

The present invention relates to microspheres and a preparation method therefor, the microspheres comprising: ropivacaine, a salt thereof, a hydrate or a solvate thereof, which have the effect of regulating acute pain after surgery; a nonsteroidal anti-inflammatory drug (NSAID); and a biodegradable polymer. The present invention provides a pharmaceutical composition for providing sustained and effective analgesic effects of ropivacaine and a nonsteroidal anti-inflammatory agent. The preparation of the present invention is applicable to all diseases in which acute pain control effects can be exhibited, and, particularly, has an improved sustained-release profile of ropivacaine and a nonsteroidal anti-inflammatory agent and simultaneously controls the release of the two drugs, can continuously provide effective analgesic effects, and can significantly increase medication compliance. In addition, conversion from a liquid solution to dry powder proceeds in a single step, and thus the microsphere preparation method of the present invention has advantages in terms of cost, scaling up, and process simplification.

A bioresorbable, sustained release pharmaceutical composition comprising: 1.8 wt % to 3.0 wt % methylcellulose and 0.1 wt % to 3.0 wt % hyaluronan in the form of a gel polymer matrix, and at least one local anesthetic agent, suitably ropivacaine, which may be administered by injection.

The invention discloses a long-acting analgesic medicine for anterior saw muscle plane block and application of the long-acting analgesic medicine, and relates to the technical field of biological pharmacy, the long-acting analgesic medicine for anterior saw muscle plane block comprises ropivacaine and methylene blue, the concentration of the ropivacaine is 0.5-1.0%, the concentration of the methylene blue is 0.5-1.0%, and the concentration of the methylene blue is 0.5-1.0%. The concentration of the methylene blue is 0.5%-2.0%; the medicine is used for anterior saw muscle plane block after prosthetic breast augmentation. It is clear for the first time that compared with independent use of ropivacaine, when methylene blue and ropivacaine are used in anterior saw muscle plane block, acute pain in the hospitalization period of prosthetic breast augmentation can be effectively relieved, a stable analgesic effect is provided within 72 hours after an operation, and long-acting analgesia can be achieved; the analgesic medicine has the advantage of low cost; the addition of methylene blue does not increase the occurrence rate of adverse reactions, and the method has good safety and wide application potential.

A lipid pharmaceutical preparation and application thereof. The lipid pharmaceutical preparation comprises a local anesthetic and a lipid substance. The mass percentage of the local anesthetic in the lipid pharmaceutical preparation is 2%-50%. The local anesthetic is lidocaine, tetracaine, bupivacaine, articaine, cinchocaine, dibucaine, etidocaine, levobupivacaine, mepivacaine, prilocaine, ropivacaine, trimecaine, benzocaine, or procaine. The mass percentage of the lipid substances in the lipid pharmaceutical preparation is 30%-98%. The sum of the mass percentages of the components in the lipid pharmaceutical preparation is 100%. In general analgesic application, the lipid pharmaceutical preparation can produce continuous and safe analgesic effects for 12, 24, 36, 48, or 72 hours, or even longer.

This invention provides a dextro-ketoprofen tromethamine patch and its preparation method. The preparation method includes: S100, using raw materials including dextro-ketoprofen tromethamine, first polyacrylic acid, poly-N-isopropylacrylamide, chitosan, and titanium dioxide, preparing ketoprofen nanofibers by electrospinning; S200, using raw materials including ropivacaine, L-phenylalanine, second polyacrylic acid, and tetraethyl orthosilicate, preparing a matrix sol by a sol-gel method; S300, mixing the ketoprofen nanofibers and the matrix sol, and performing a gelation treatment to prepare the dextro-ketoprofen tromethamine patch. The dextro-ketoprofen tromethamine patch obtained by this invention has good photostability and a good sustained-release effect.

A bioresorbable, sustained release pharmaceutical composition comprising: 1.8 wt % to 3.0 wt % methylcellulose and 0.1 wt % to 3.0 wt % hyaluronan in the form of a gel polymer matrix, and at least one local anesthetic agent, suitably ropivacaine, which may be administered by injection.

The present application relates to a kind of epidural delivery analgesia injection systems, comprising: judging module, for receiving epidural puncture tube backflow liquid, puerpera pain condition and the situation of birth canal, and according to liquid, puerpera pain condition and the situation of birth canal judging injection mode;Calculation module, for receiving injection mode from judging module, and according to injection mode calculation injection parameter;And injection module, for receiving injection parameter from calculation module after injection drug, including: first injection module, for injecting sufentanil;And second injection module, for injecting ropivacaine;Wherein, injection mode includes: intermittent injection and progressive injection;Injection parameter includes: injection process, injection drug, drug concentration, drug volume and interval time;The present application is automatically and finely dosed injection by calculation module and injection module, can improve the safety, effectiveness and delivery analgesia rate when delivery analgesia, to avoid puerpera's fear of delivery.

The invention relates to the field of pharmaceutical preparations, and particularly provides a ropivacaine sustained-release solution preparation based on a phospholipid complex and a preparation method thereof, and the preparation has the advantages of increased drug loading capacity, good safety, no obvious stimulation to administration tissues and long sustained-release time.

The invention relates to the field of mass spectrometric detection, and discloses a rapid quantitative analysis method for plasma concentration of ropivacaine, which relates to the field of mass spectrometric detection, and comprises the following steps: preparing a ropivacaine standard curve sample and a quality control sample; carrying out pretreatment on the standard curve sample, the quality control sample and the sample to be detected by adopting a method of solid-phase extraction after protein precipitation; then performing sample injection detection by adopting a mass spectrometry method; and establishing a regression equation according to the standard curve sample, and calculating the concentration of ropivacaine in the to-be-detected sample. According to the invention, the rapid quantitative detection of the concentration of ropivacaine in human plasma / serum / whole blood can be realized, the linear range concentration of ropivacaine is 10-10000 ng / mL, and the concentrations of quality control samples are 3 ng / mL, 400 ng / mL, 4000 ng / mL and 7500 ng / mL. The detection sensitivity is high, the linear range is wide, the accuracy is high, the analysis speed is high, convenience and rapidness are achieved, and support is provided for rapid monitoring of clinical blood concentration and reasonable medication of ropivacaine.

The present invention is within the technical field of pain-relief and relates to a pharmaceutical composition comprising at least one anesthetic agent selected from the group consisting of ropivacaine, bupivacaine, etidocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, articaine, dibucaine, levobupivacaine, prilocaine, benzocaine, chloroprocaine, cocaine, procaine, proparacaine, tetracaine and any pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof; at least one alkanolamine selected from the group consisting of triethanolamine, tripropanolamine and trimethanolamine; water; and optionally a pharmaceutically acceptable diluent, carrier and / or excipient. The present disclosure furthermore relates to the use of the composition for providing pain-relief, a method of treatment, a method of producing said pharmaceutical composition as well as a carbon quantum dot formed from components of the pharmaceutical composition.

Compositions of ropivacaine or a pharmaceutically acceptable salt thereof and uses thereof are provided. The suspension and the solid composition can be sterilized and filtered to ensure the sterile level, and the obtained composition is good in stability, controllable in product quality, easy to administrate, small in irritation and good in medication safety and tolerance.

The invention discloses a composition composed of diclofenac and ropivacaine and having amorphous substance characteristics and a preparation method of the composition. The composition has no obvious characteristic XRD (X-Ray Diffraction) peak. The preparation method of the composition comprises a solvent method, a coprecipitation method and a melting method. The diclofenac ropivacaine composition provided by the invention has the advantages of simple preparation process, good long-term storage stability and the like, and has the potential of being developed into a preparation.